(NP (NP Glucocorticoid-mediated/JJ inhibition/NN) (PP of/IN (NP (NP RANTES/NN expression/NN) (PP in/IN (NP human/JJ T/NN lymphocytes/NNS)))) ./.)
(S (NP-SBJ-51 The/DT chemokine/NN RANTES/NN) (VP has/VBZ (VP been/VBN (VP implicated/VBN (NP *-51/-NONE-) (PP in/IN (NP (NP the/DT pathogenesis/NN) (PP of/IN (NP (NP allergic/JJ inflammatory/JJ diseases/NNS) (PP including/VBG (NP (NP-COOD (NP asthma/NN) and/CC (NP rhinitis/NN)) (SBAR (WHNP-52 which/WDT) (S (NP-SBJ-53 *T*-52/-NONE-) (VP are/VBP (VP (ADVP-TMP frequently/RB) treated/VBN (NP *-53/-NONE-) (PP with/IN (NP glucocorticoids/NNS))))))))))))))) ./.)
(S (NP-SBJ We/PRP) (VP observed/VBD (SBAR that/IN (S (NP-SBJ dexamethasone/NN) (ADVP dramatically/RB) (VP inhibited/VBD (NP RANTES/NN mRNA/NN expression/NN) (ADVP dose/NN dependently/RB) (PP in/IN (NP-COOD (NP (ADJP anti-CD3/NN activated/JJ) Hut-78/NN T/NN cells/NNS) and/CC (NP human/JJ PBMCs/NNS))))))) ./.)
(S (NP-SBJ-54 (NP Inhibition/NN) (PP of/IN (NP RANTES/NNS expression/NN))) (VP-COOD (VP did/VBD not/RB (VP appear/VB (S (NP-SBJ *-54/-NONE-) (VP to/TO (VP be/VB (ADJP-PRD secondary/JJ (PP to/TO (NP IL-2/NN inhibition/NN)))))))) and/CC (VP required/VBD (NP (NP binding/VBG) (PP to/TO (NP the/DT intracellular/JJ glucocorticoid/NN receptor/NN))))) ./.)
(S (NP-SBJ (NP The/DT down-regulation/NN) (PP of/IN (NP RANTES/NN expression/NN)) (PP by/IN (NP (NP glucocorticoids/NNS) (PP in/IN (NP T/NN cells/NNS))))) (VP may/MD (VP (ADVP directly/RB) contribute/VB (PP-COOD (PP to/TO (NP (NP the/DT efficacy/NN) (PP of/IN (NP these/DT agents/NNS)) (PP in/IN (S (NP-SBJ */-NONE-) (VP suppressing/VBG (NP cellular/JJ infiltration/NN)))))) and/CC (PP to/TO (NP their/PRP$ anti-inflammatory/JJ properties/NNS))))) ./.)
